Assessment of αvβ3 integrin expression after myocardial infarction by positron emission tomography

Cardiovascular Research

Volumn 78, Issue 2, 2008, Pages 395-403

  Higuchi, Takahiro ^a   Bengel, Frank M ^a   Seidl, Stefan ^a   Watzlowik, Petra ^a   Kessler, Horst ^b   Hegenloh, Renate ^a   Reder, Sybille ^a   Nekolla, Stephan G ^a   Wester, Hans J ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Endothelial receptors; Infarction; Ischaemia; Reperfusion

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CYCLO(ARGINYLGLYCYLASPARTYL DEXTRO PHENYLALANYLVALINE); GALACTOARGINYLGLYCYLASPARTIC ACID F 18; RECEPTOR BLOCKING AGENT; THALLIUM 201; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; CD31 ANTIGEN; CYCLO(ARGINYL GLYCYL ASPARTYL PHENYLALANYL VALYL); CYCLO(ARGINYL-GLYCYL-ASPARTYL-PHENYLALANYL-VALYL); CYCLOPEPTIDE; DRUG DERIVATIVE; FLUOROGALACTO RGD; FLUOROGALACTO-RGD; GALACTOSE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART SCINTISCANNING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOISOTOPE DISTRIBUTION; RAT; ANGIOGENESIS; ANIMAL; AUTORADIOGRAPHY; CORONARY BLOOD VESSEL; DISEASE MODEL; DRUG ANTAGONISM; FEASIBILITY STUDY; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SCINTISCANNING; TIME; WISTAR RAT;

ANIMALS; ANTIGENS, CD31; AUTORADIOGRAPHY; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; GALACTOSE; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TIME FACTORS;

EID: 42349091473     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn033     Document Type: Article

References (43)

1. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation 1992;85:1197-1204.
2. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005;112:1813-1824.
3. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-1032.
4. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 2004;109:2692-2697.
5. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 2004;109:2487-2491.
6. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-793.
7. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365.
8. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677-2683.
9. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684- 1691.
10. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M et al. Non-invasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.
11. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15:61-69.
12. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10:1439-1455.
13. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781-1785.
14. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333-1341.
15. Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006;47:763-769.
16. Higuchi T, Taki J, Nakajima K, Kinuya S, Namura M, Tonami N. Time course of discordant BMIPP and thallium uptake after ischemia and reperfusion in a rat model. J Nucl Med 2005;46:172-175.
17. Higuchi T, Nekolla SG, Jankaukas A, Weber AW, Huisman MC, Reder S et al. Characterization of normal and infarcted rat myocardium using a combination of small-animal PET and clinical MRI. J Nucl Med 2007;48:288-294.
18. Ikeda Y, Miura T, Sakamoto J, Miki T, Tanno M, Kobayashi H et al. Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation. Basic Res Cardiol 2006;101:418-426.
19. Tanno M, Tsuchida A, Nozawa Y, Matsumoto T, Hasegawa T, Miura T et al. Roles of tyrosine kinase and protein kinase C in infarct size limitation by repetitive ischemic preconditioning in the rat. J Cardiovasc Pharmacol 2000;35:345-352.
20. Taki J, Higuchi T, Kawashima A, Tait JF, Kinuya S, Muramori A et al. Detection of cardiomyocyte death in a rat model of ischemia and reperfusion using 99mTc-labeled annexin V. J Nucl Med 2004;45:1536-1541.
21. Maskali F, Poussier S, Marie PY, Tran N, Antunes L, Olivier P et al. High-resolution simultaneous imaging of SPECT, PET, and MRI tracers on histologic sections of myocardial infarction. J Nucl Cardiol 2005;12:229-230.
22. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 1991;291:50-54.
23. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, Kessler H et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 1994;269:20233-20238.
24. Toyota E, Matsunaga T, Chilian WM. Myocardial angiogenesis. Mol Cell Biochem 2004;264:35-44.
25. Tomanek RJ, Schatteman GC. Angiogenesis: new insights and therapeutic potential. Anat Rec 2000;261:126-135.
26. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-1297.
27. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006;13:1503-1511.
28. Simons M, Bonow RO, Chronos NA, Cohen DJ, Giordano FJ, Hammond HK et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000;102:E73-E86.
29. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation 2003;108:2613-2618.
30. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-571.
31. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997;71:320-324.
32. Wu WB, Peng HC, Huang TF. Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell-cell and cell-ECM interactions in regulating cell viability. Exp Cell Res 2003;286:115-127.
33. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 2006;12:2723-2747.
34. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500-1502.
35. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001;48:151-157.
36. Hua J, Dobrucki LW, Sadeghi MM, Zhang J, Bourke BN, Cavaliere P et al. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 2005;111:3255-3260.
37. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 2006;47:113-121.
38. Blankesteijn WM, Creemers E, Lutgens E, Cleutjens JP, Daemen MJ, Smits JF. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand 2001;173:75-82.
39. Jugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 2003;108: 1395-1403.
40. Ertl G, Frantz S. Healing after myocardial infarction. Cardiovasc Res 2005;66:22-32.
41. Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 2005;7:223-253.
42. Nelissen-Vrancken HJ, Debets JJ, Snoeckx LH, Daemen MJ, Smits JF. Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. Circulation 1996;93:349-355.
43. Leong-Poi H, Christiansen J, Heppner P, Lewis CW, Klibanov AL, Kaul S et al. Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation 2005;111:3248-3254.